Results 41 to 50 of about 10,632 (179)
mBio, 2018 Darunavir (DRV) has bimodal activity against HIV-1 protease, enzymatic inhibition and protease dimerization inhibition, and has an extremely high genetic barrier against development of drug resistance. We previously generated a highly DRV-resistant HIV-1
Manabu Aoki +6 more
doaj +1 more source
HIV Research & Clinical Practice, 2020 Antiretroviral therapies have been tested with the goal of maintaining virological suppression with a particular attention in limiting drug-related toxicity.
Valentina Di Cristo +14 more
doaj +1 more source
HIV Medicine, Volume 27, Issue 7, Page 1132-1143, July 2026.Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson +13 more
wiley +1 more source
Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
HIV/AIDS: Research and Palliative Care, 2016 Jordi Navarro, Adrian Curran Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is
Navarro J, Curran A
doaj
Brazilian Journal of Infectious Diseases, 2013 Objectives: To assess the virologic and immunological response of darunavir/ritonavir plus optimized background therapy in highly antiretroviral-experienced HIV-infected patients in Brazil.
José Ernesto Vidal +11 more
doaj +1 more source
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
BMC Infectious Diseases, 2019 Background Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking.
Alberto Borghetti +12 more
doaj +1 more source
Chemical Biology &Drug Design, Volume 107, Issue 6, June 2026.Three decades of cruzain‐targeted drug discovery have yielded 215 sub‐micromolar inhibitors but no clinical candidates. This review diagnoses a systemic translational failure driven by single‐parameter optimisation and proposes a multiparametric framework integrating enzymatic potency, cathepsin selectivity, intracellular exposure, and metabolic ...
Caroline Rodrigues Chaves dos Reis +7 more
wiley +1 more source
Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
Therapeutics and Clinical Risk Management, 2009 Michael Neely, Andrea KovacsUniversity of Southern California Keck School of Medicine, Department of Pediatrics, Division of infectious Diseases, Los Angeles, CA, USAAbstract: Darunavir is currently the most recently approved HIV-1 protease inhibitor. It
Michael Neely, Andrea Kovacs
doaj
HIV Research & Clinical Practice, 2019 Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection.
Bruce Rashbaum +8 more
doaj +1 more source